SCHEMBL4108537

SCHEMBL4108537

c1cc(N2CCCCCC2)nc(N[C@H]2CCN(C3CCCCC3)[C@@H]2CCCN2CCOCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.42
▸ HRH4 Q9H3N8 7/20 0.41
▸ MKNK1 Q9BUB5 2/20 0.38
▸ OGA O60502 2/20 0.38
▸ CCNK O75909 2/20 0.36
▸ CDK12 Q9NYV4 2/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.35
▸ MRGPRX1 Q96LB2 1/20 0.35
▸ ADRA2B P18089 1/20 0.34
▸ ADRA2C P18825 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ GSK3B P49841 1/20 0.34
▸ AURKA O14965 1/20 0.33
▸ CDK1 P06493 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2014636 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL2010314 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL2010406 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL4105627 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL4108575 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL4103950 0.94 HRH4 (0.45) CXCR4HRH4MKNK1OGADRD2
SCHEMBL4110612 0.90 HRH4 (0.52) CXCR4HRH4OGADRD2DRD3
SCHEMBL4116679 0.90 CXCR4 (0.42) CXCR4HRH4OGADRD2DRD3
SCHEMBL4116401 0.89 HRH4 (0.46) CXCR4HRH4DRD2DRD3
SCHEMBL13696670 0.88 HRH4 (0.47) CXCR4HRH4OGADRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680092-B2 Nitrogenous heterocyclic compound and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 — — US disclosed
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2009-09-17 — — US disclosed
EP-1852432-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2007-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233908-A1 NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF CXCR4, CXCR1, CXCL12 CXCR4 1/4885HRH4 152/4885MKNK1 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback